This is a distressed capital raise by a company with a going-concern warning and only weeks of cash runway. The lack of a minimum offering amount means the company could close with far less than $3.4 million, extending the runway only marginally. Monitor the final pricing and number of shares sold — if the offering is undersubscribed, the company may face an imminent liquidity crisis. The 146% CyPath Lung unit growth is positive but on a tiny base and does not offset the 36% consolidated revenue decline.
Executive Summary
bioAffinity Technologies filed an S-1 registration statement for a best-efforts public offering of up to 2,631,579 shares of common stock and pre-funded warrants at an assumed price of $1.52 per share, targeting approximately $3.4 million in net proceeds for working capital. The company has a going-concern warning, with only $3.1 million cash on hand as of March 31, 2026, and an accumulated deficit of $72.2 million. While CyPath Lung unit sales grew 146% YoY in Q1 2026, consolidated revenue declined 36% to $1.4 million, and the company's auditor has raised substantial doubt about its ability to continue as a going concern.
Key Financial Metrics
Key Facts
- Offering of up to 2,631,579 shares of common stock at an assumed price of $1.52 per share, plus pre-funded warrants
- Estimated net proceeds of approximately $3.4 million for working capital and general corporate purposes
- Going-concern warning from auditor WithumSmith+Brown, PC in the 2025 audited financial statements
- Cash on hand of $3.1 million as of March 31, 2026, with management stating cash sufficient only through June 2026 without additional funding
- Accumulated deficit of $72.2 million as of March 31, 2026
- Consolidated revenue declined 36% to $1.4 million for Q1 2026 vs $1.9 million in Q1 2025
- CyPath Lung testing revenue increased 114% to $361,000 in Q1 2026, but unit sales growth of 146% is on a small base
- No minimum offering amount — the company may sell fewer shares, reducing proceeds significantly
- Immediate dilution of $0.78 per share for new investors based on the assumed offering price
- No underwriter — WallachBeth Capital is acting as placement agent on a reasonable best-efforts basis
Financial Impact
Approximately $3.4 million net proceeds targeted, but no minimum offering amount creates risk of substantially lower proceeds. The company's cash runway is critically short (through June 2026 only).
Risk Factors
- Going-concern risk — cash only sufficient through June 2026 without this offering
- No minimum offering amount — proceeds could be far below $3.4 million, insufficient to fund operations
- Consolidated revenue declining 36% YoY despite CyPath Lung growth
- Massive dilution — 55% increase in shares outstanding from 4.7M to 7.4M, plus $0.78 per share dilution to new investors
- Heavy warrant overhang — 1.7M warrants at $22.38 exercise price (deep out of the money) and 386K options at $6.52
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-028507 |
| Exhibit: ex107.htm | 0001493152-26-028507 |
| Exhibit: ex5-1.htm | 0001493152-26-028507 |
| Exhibit: ex23-1.htm | 0001493152-26-028507 |
| Document: 0001493152-26-028507-index-headers.html | 0001493152-26-028507 |
| Document: 0001493152-26-028507-index.html | 0001493152-26-028507 |
| Document: 0001493152-26-028507.txt | 0001493152-26-028507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEF 14A | $2.83 | awaiting T+60 | — | $2.96 (+4.59%) |
Oct 15, 2026 12d ago | 8-K | $3.96 | awaiting T+60 | — | $2.96 (−25.25%) |
Oct 13, 2026 14d ago | 8-K | $3.63 | awaiting T+60 | — | $2.96 (−18.34%) |
Oct 9, 2026 18d ago | 8-K | $3.90 | awaiting T+60 | — | $2.96 (+24.10%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (+37.35%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (−37.35%) |
Oct 8, 2026 19d ago | 8-K | $5.64 | awaiting T+60 | — | $2.96 (−47.52%) |
Oct 6, 2026 21d ago | 8-K | $6.06 | awaiting T+60 | — | $2.96 (−51.16%) |
Sep 30, 2026 27d ago | 8-K | $6.56 | awaiting T+60 | — | $2.96 (−54.88%) |
Sep 22, 2026 5w ago | 8-K | $8.56 | awaiting T+60 | — | $2.96 (−65.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers